MBHB Partner Kevin Noonan comments on biosimilar patent battle
March 30, 2023
In BioPharmaDive, MBHB Partner Kevin Noonan, Ph.D., discusses how Johnson & Johnson is seeking to ward off biosimilar competition to its psoriasis drug Stelera from Amgen. View the article.
